E-viri
Recenzirano
-
Zagonel, V; Tirelli, U; Veronesi, A; Galligioni, E; Tumolo, S; Roncadin, M; Carbone, A; Grigoletto, E
Blut 52, Številka: 1Journal Article
Teniposide has been evaluated in a phase II clinical trial in chronic lymphocytic leukemia (CLL). Among 16 consecutive patients with CLL entered in the study and treated with Teniposide, 100 mg/m2 weekly, no objective response was observed. Toxicity was generally mild and mainly hematologic. Teniposide at this dosage and schedule is an inactive drug in CLL.
